PE20000381A1 - Nuevas formulaciones de paroxetina - Google Patents

Nuevas formulaciones de paroxetina

Info

Publication number
PE20000381A1
PE20000381A1 PE1998001126A PE00112698A PE20000381A1 PE 20000381 A1 PE20000381 A1 PE 20000381A1 PE 1998001126 A PE1998001126 A PE 1998001126A PE 00112698 A PE00112698 A PE 00112698A PE 20000381 A1 PE20000381 A1 PE 20000381A1
Authority
PE
Peru
Prior art keywords
paroxetine
presented
solid
semi
refers
Prior art date
Application number
PE1998001126A
Other languages
English (en)
Inventor
Ghazawi Ahmad
Leonard Graham Stanley
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE20000381A1 publication Critical patent/PE20000381A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE SE PRESENTA EN FORMA DE CAPSULA QUE CONTIENE 1)PAROXETINA O LA BASE LIBRE O EL HEMIHIDRATO O EL ANHIDRATO DEL HIDROCLORURO O HIDROCLORURO AMORFO O ANHIDRATO CRISTALINO; 2)VEHICULO QUE SE PUEDEN PRESENTAR COMO a)LIQUIDO FLUIBLE O LIQUIDO VISCOSO O SEMISOLIDO O GEL; b)SOLIDO O SEMISOLIDO COMO CERAS Y GRASAS NATURALES O SINTETICAS; c)POLIMEROS QUE FORMAN PELICULAS O TERMOPLASTICOS; 3)EXCIPIENTES HIDROFOBOS O ANHIDROS. LA COMPOSICION TAMBIEN SE PUEDE PRESENTAR EN FORMA DE TABLETAS, PERLAS, ESFERULAS, GRANULOS, PASTILLAS O GELES; QUE PUEDE ESTAR REVESTIDA PARA RETARDAR O CONTROLAR LA LIBERACION DE PAROXETINA O PARA ENMASCARAR EL SABOR O PARA FACILITAR SU ADMINISTRACION. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LA PAROXETINA ES UTIL PARA EL TRATAMIENTO Y PROFILAXIS DE DEPRESION, TRASTORNO COMPULSIVO OBSESIVO Y PANICO
PE1998001126A 1997-11-21 1998-11-18 Nuevas formulaciones de paroxetina PE20000381A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9724544.3A GB9724544D0 (en) 1997-11-21 1997-11-21 Novel Formulation

Publications (1)

Publication Number Publication Date
PE20000381A1 true PE20000381A1 (es) 2000-05-07

Family

ID=10822374

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001126A PE20000381A1 (es) 1997-11-21 1998-11-18 Nuevas formulaciones de paroxetina

Country Status (24)

Country Link
EP (1) EP1033986A1 (es)
JP (1) JP2001523718A (es)
KR (1) KR20010032320A (es)
CN (1) CN1279608A (es)
AP (1) AP2000001821A0 (es)
AR (1) AR015485A1 (es)
AU (1) AU1168099A (es)
BG (1) BG104527A (es)
BR (1) BR9814220A (es)
CO (1) CO4970832A1 (es)
DZ (1) DZ2658A1 (es)
EA (1) EA200000552A1 (es)
GB (1) GB9724544D0 (es)
HU (1) HUP0100580A3 (es)
IL (1) IL136106A0 (es)
MA (1) MA24704A1 (es)
NO (1) NO20002590L (es)
OA (1) OA11385A (es)
PE (1) PE20000381A1 (es)
PL (1) PL340555A1 (es)
SK (1) SK7342000A3 (es)
TR (1) TR200001423T2 (es)
WO (1) WO1999026625A1 (es)
ZA (1) ZA9810637B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810180D0 (en) * 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulation
CA2367402C (en) * 1999-03-12 2010-11-23 Basf Aktiengesellschaft Stable pharmaceutical dosage form for paroxetine anhydrate
WO2001002393A1 (en) 1999-07-01 2001-01-11 Italfarmaco S.P.A. Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives
DE19930454A1 (de) * 1999-07-02 2001-01-04 Knoll Ag Feste Paroxetin enthaltende Zubereitungen
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
ES2294197T3 (es) * 2001-12-21 2008-04-01 Supernus Pharmaceuticals, Inc. Formulacion de capsula oral con estabilidad fisica aumentada.
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
US20120322752A1 (en) * 2009-12-08 2012-12-20 Sung Kyun Lee SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
HUP0000960A3 (en) * 1997-01-15 2001-04-28 Smithkline Beecham Plc Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
BG104527A (en) 2001-04-30
AU1168099A (en) 1999-06-15
OA11385A (en) 2004-01-27
MA24704A1 (fr) 1999-07-01
ZA9810637B (en) 2000-05-22
DZ2658A1 (fr) 2003-03-22
BR9814220A (pt) 2001-12-26
EP1033986A1 (en) 2000-09-13
HUP0100580A2 (hu) 2002-04-29
NO20002590D0 (no) 2000-05-19
PL340555A1 (en) 2001-02-12
NO20002590L (no) 2000-07-19
EA200000552A1 (ru) 2000-10-30
TR200001423T2 (tr) 2000-10-23
JP2001523718A (ja) 2001-11-27
SK7342000A3 (en) 2000-12-11
CN1279608A (zh) 2001-01-10
CO4970832A1 (es) 2000-11-07
IL136106A0 (en) 2001-05-20
WO1999026625A1 (en) 1999-06-03
HUP0100580A3 (en) 2002-05-28
GB9724544D0 (en) 1998-01-21
AR015485A1 (es) 2001-05-02
KR20010032320A (ko) 2001-04-16
AP2000001821A0 (en) 2000-06-30

Similar Documents

Publication Publication Date Title
ES2037082T3 (es) Una composicion para la liberacion controlada de un farmaco.
PE20000381A1 (es) Nuevas formulaciones de paroxetina
ES2201361T3 (es) Formulacion topica que contiene un tampon fosfato con estimulador de la permeabilidad cutanea.
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
ES2189868T3 (es) Microesferas y nanoesferas biodegradables de liberacion controlada que contienen ciclosporina.
BR0012869A (pt) Forma de dosagem farmacêutica de componentes múltiplos
ATE248589T1 (de) Matrix zur gesteuerten freisetzung von arzneistoffen
ES2156198T3 (es) Composiciones para envoltorios de capsulas, y utilizacion de las mismas.
ES2187822T3 (es) Comprimidos de disgregacion rapida.
PT93170A (pt) Processo para a preparacao de dispositivos distribuidores nomeadamente de capsulas contendo um ingrediente activo
AR013947A1 (es) Composicion farmaceutica para combinacion de piperidinoalcanol- descongestionante
PT797991E (pt) Formulacao com libertacao prolongada contendo venlafaxina
AR022085A1 (es) Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida
EA199900964A1 (ru) Соли сертралина и лекарственные формы с длительным высвобождением сертралина
PT1028707E (pt) Formulacoes oftalmicas de libertacao controlada contendo medicamentos soluveis em agua
AU1810783A (en) Constant release tablet formulation
PE71699A1 (es) Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
UA42061C2 (uk) Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
ATE121302T1 (de) Transdermales therapeutisches system mit dem wirkstoff tulobuterol.
ATE517615T1 (de) Schmerzstillendes und entzündungshemmendes pflaster zur lokalen anwendung
DE60321386D1 (de) Pharmazeutische zubereitung zur modifizierten freisetzung
ES2158101T3 (es) Formulaciones farmaceuticas efervescentes que contienen microcapsulas biodegradables de liberacion controlada.
DE69904922D1 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
ATE243504T1 (de) Cefadroxilmonohydrat tablettenformulierung

Legal Events

Date Code Title Description
FC Refusal